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Background to the debate: Umbilical cord blood—the blood that remains in the placenta after birth—can be 
collected and stored frozen for years. A well-accepted use of 
cord blood is as an alternative to bone marrow as a source of 
hematopoietic stem cells for allogeneic transplantation to 
siblings or to unrelated recipients; women can donate cord 
blood for unrelated recipients to public banks. However, 
private banks are now open that offer expectant parents 
the option to pay a fee for the chance to store cord blood 
for possible future use by that same child (autologous 
transplantation.)
Nicholas Fisk and Irene Roberts’s Viewpoint: 
There Are Good Reasons to Be Wary of Private 
Banking
No one disputes the merit of public cord blood banking, 
in which women altruistically donate umbilical cord blood 
(UCB) for haemopoietic stem cell (HSC) transplantation, 
in a way similar to bone marrow donation. Unrelated 
UCB transplants have good outcomes in children and are 
associated with less graft-versus-host disease than adult 
marrow or peripheral blood stem cells [1,2]. Public cord 
blood banks also increase the availability of donor HSCs for 
ethnic groups underrepresented in bone marrow registries 
[3]. Similarly, there is little argument against storing UCB 
from siblings in families with a known genetic disease 
amenable to HSC transplantation [4]. 
The validity of directed UCB storage in “low risk” families, 
however, has been widely challenged. After early concerns 
from the American Academy of Pediatrics [5] and American 
College of Obstetricians and Gynecologists [6], the United 
Kingdom’s Royal College of Obstetricians and Gynaecologists 
concluded in 2001 that routine, directed commercial UCB 
storage could not be justiﬁ ed scientiﬁ cally, was logistically 
difﬁ cult, and therefore could not be recommended [7]. In 
2002, the French National Consultative Ethics Committee for 
Health and Life Sciences reached similar conclusions [8]. In 
Italy the practice has been banned. A recent European Union 
report highlighted serious ethical concerns about commercial 
UCB banks and questioned their legitimacy in selling a 
service of no real use [9]. So what’s wrong with allowing 
parents who can afford it the biological luxury of storing their 
child’s stem cells? 
First, UCB is very unlikely ever to be used. The probability 
of needing an autologous transplant is less than one in 20,000 
[9,10], although commercial providers quote ﬁ gures at least 
an order of magnitude higher, often confusing prearranged 
usage in at risk children with unanticipated use in those 
at low risk. For acute leukaemia, perhaps the most likely 
indication for autologous UCB transplantation, improvements 
in conventional therapy and allogeneic transplantation mean 
few proceed to autologous transplantation. In any case, 
there are arguments against the use of autologous UCB, 
including the presence of pre-leukaemic mutations and the 
high rate of relapse [11]. Similar considerations apply to 
bone marrow failure [11]. Of current indications for HSC 
transplantation [12], only for solid tumours, lymphomas, and 
auto-immune disorders might autologous UCB ﬁ nd a role, 
and even here, UCB collections often contain only enough 
HSCs to reconstitute children (not adults). Other uses for 
UCB remain speculative since it is unclear whether non-
haemopoietic stem cells are present in sufﬁ cient numbers for 
use against degenerative conditions. Even in the uncommon 
event of a requirement for autologous stem cells, failure 
to store UCB is unlikely to be disastrous; HSCs could still 
be harvested from bone marrow or peripheral blood, and 
multipotent stem cells are increasingly being isolated from 
other accessible sources (e.g., deciduous teeth). 
Second, there are important moral issues. The persuasive 
promotional materials of commercial UCB banks target 
parents at a vulnerable time, urging them to take this “once in 
a lifetime opportunity” to “save the key components to future 
medical treatment” and freeze “a spare immune system” 
[7]. Even at a typical cost of several thousand dollars, how 
could any responsible parent fail to provide for their child’s 
future by preserving “something that may conceivably save 
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his or her life”? As well as enumerating conditions currently 
treated by HSC transplantation, such literature boasts lengthy 
lists of diseases potentially amenable to stem cell therapy in 
the future, including Parkinson disease, diabetes, cancer, 
and heart disease. Such banks have been said to raise hopes 
of utopia and to use the promise of “helping children” to 
disguise a mercantile project 
Third, collection imposes a considerable logistic burden 
on the obstetrician or midwife. In addition to consent, 
parental blood collection, and the associated packaging and 
paperwork, a large volume of blood has to be collected from 
the umbilical vessels in utero, requiring multiple syringes 
under aseptic technique. This may distract professionals from 
their primary task of caring for the mother and baby at this 
risky time or, more generally, divert delivery room staff from 
attending others [7]. This applies particularly in multiple 
or operative deliveries, and thus UCB collection is not 
recommended at complicated births [5]. These problems do 
not apply to altruistic donations to public cord blood banks, 
which can be harvested less intrusively ex utero; inadequate 
or logistically difﬁ cult samples can be discarded or forgone 
without consequence [3].
Finally, individual UCB banks need to remain in business 
long term if cryopreserved stem cells are to be retrieved. 
The commercial attractiveness of a service paid years in 
advance is attested to by the burgeoning number of private 
providers, yet it seems unlikely that all will survive. Indeed, 
some US providers are already in trouble for infringing 
collection patents. There remain reservations about whether 
laboratories will meet national standards and be accredited. 
There is a further danger that misplaced enthusiasm for 
commercial auto-collection will undermine the proven utility 
of altruistic public cord blood banks. 
Notwithstanding the above, we accept that the utility of UCB 
storage in low-risk families is very different from the entirely 
speculative post-mortem cryonics industry. We acknowledge 
the possibility that autologously stored UCB stem cells may 
eventually be used. Indeed, recent research documenting the 
multi-potentiality of UCB mesenchymal lineages [13] and 
the in vitro expandability of cord HSC numbers sufﬁ cient to 
transplant an adult [14,15] may even improve such prospects. 
Private banks, however, must provide clear, honest, and 
unambiguous information for their customers. EU guidance 
recommends they be told that the likelihood of stored UCB 
stem cells being used to treat their child is negligible and that 
future therapeutic possibilities are very hypothetical [9].
Roger Markwald and Vladimir Mironov’s 
Viewpoint: No One Has a Second Chance to 
Collect Their Cord Blood
Stem cells may potentially be used in life-saving therapies 
for degenerative diseases or injuries. Stem cells self-replicate 
and are multi-potential—they can differentiate into diverse 
cell types [13]. While stem cells can come from many 
sources, our viewpoint is that UCB is an important source 
of progenitor (stem) cells that can be used as an immediate 
alternative for bone marrow transplantation and for 
engineering healthy new cells and tissues. 
To fully realize this potential will require collection and 
banking of UCB cells, which are harvested without pain or 
trauma from placental structures that are normally discarded 
after birth. We realize that UCB banking (public and private) 
has sparked controversy. Critics of routine banking question 
its cost-to-beneﬁ t ratio, citing doubts about the clinical 
relevance of cord stem cells or the likelihood that they will 
ever be used [16]. Other critics argue that embryonic stem 
cells (ESCs) are the better option. 
The “stemness” of UCB cells is not merely theoretical (as 
suggested by Steinbrook; [16]). UCB has two types of multi-
potential progenitor cells—HSCs and mesenchymal stem 
cells. These express different cell surface markers, making 
it possible to show that HSCs can differentiate into new red 
and white blood cells and, as with mesenchymal stem cells, 
can also transdifferentiate in vivo into liver, kidney, brain, 
bone, skeletal, and cardiac muscle cells [13,17,18,19,20]. 
While ESCs have the potential to form all types of cells, they 
are harvested from embryos shortly after fertilisation, raising 
moral and legal issues not attributed to UCB cells [21]. 
ESCs also represent an allogeneic source of cells—they are 
derived from another individual whose tissue type does not 
match up with the recipient, resulting in immune rejection 
when transplanted [22]. We know of no clinical or preclinical 
animal study that provides hard evidence of functional 
integration (without immune rejection) of transplanted ESCs. 
Even with somatic nuclear transfer (cloning), ESCs remain 
allogeneic, as they still have foreign mitochondrial DNA for 
which there remains untested potential risk for auto-immune 
diseases. In contrast, 2,000 allogeneic UCB transplants have 
been performed, mostly in children, for the treatment of a 
variety of malignant and nonmalignant conditions [22]. A 
London Cord Blood Bank report found that two years after 
transplantation the survival rate varied between 54% and 
69%, depending upon the number of matched units [23]. 
For reasons not fully understood, allogeneically transplanted 
UCB cells have immune tolerance (of HLA mismatch) [24], 
and the risk of causing graft-versus-host disease is considered 
to be acceptable [24,25]. 
With millions of healthy babies born each year, there is 
potentially a large UCB supply that can be stored, tissue-
typed, and made available at short notice. If saved for 
potential use by the donor, UCB cells become a source of 
perfectly matched, autologous stem cells (plus there is a 
25% probability of being an exact match for a sibling). Yet 
the American Academy of Pediatrics came out against UCB 
The real question is who should 
pay for umbilical cord blood 
collection and storage.
DOI: 10.1371/journal.pmed.0020044.g002
CureSource, a commercial UCB bank, believes that banking is a “once 
in a lifetime opportunity” (Figure: CureSource)
February 2005  |  Volume 2  |  Issue 2  |  e44
PLoS Medicine  |  www.plosmedicine.org 0089
banking, saying that the odds (with some exceptions) of a 
donor ever using a UCB sample were low, between 1/1,000 
and 1/200,000. While the chance of a donor beneﬁ ting 
may presently be low, this does not automatically mean that 
another member of society could not beneﬁ t. For people 
with genetic diseases or cancers, the chances of ﬁ nding an 
immune-tolerant donor match would obviously be increased 
by the expansion of cord blood sampling. Also, at the pace 
that stem cell research is moving, perhaps there will be new 
uses for UCB cells in the next decade, especially in the ﬁ eld 
of tissue engineering [26]. Importantly, unlike bone marrow, 
an increase in UCB samples will enhance availability for every 
ethnic group for tissue matching. What is certain is that no 
one has a second chance to collect their cord blood. 
Who should operate cord blood banks—the private or the 
public sector? There are around 20 private UCB banks in the 
United States. They charge a collection fee, typically $1,000–
$1,500, which includes testing for pathogens and genotyping. 
Samples are maintained in a frozen state for around $100 a 
year. An additional $15,000–$25,000 is charged if a sample is 
used for transplantation (usually covered by health insurance). 
The cost of UCB cell transplantation is signiﬁ cantly less than 
bone marrow transplantation, and the risk of graft-versus-host 
disease is lower [24]. The private sector, not government, 
has been the innovator for most new technology related to 
harvesting, storing, and utilizing cord blood as well as stem cell 
research. Licensing fees and patent protection are essential to 
biotechnology companies—they are needed to attract venture 
capital, build businesses, and develop new technologies. The 
only alternative in most countries is public cord banks, which 
suffer from insufﬁ cient funding. 
Any exploitation by companies of the vulnerabilities of 
expectant parents for ﬁ nancial gain is clearly unacceptable. 
Federal legislation to establish a national cord blood stem 
cell bank network—free to all donors—has been introduced 
in the US Senate and House of Representatives that, if 
approved, should diminish the risk of exploitation. But unless 
the network is well-designed from a sociological viewpoint, it 
could generate a situation where not all cultural and ethnic 
groups are represented or where beneﬁ ts are accessible only 
to families with health insurance or sufﬁ cient income to 
afford transplants. It still remains difﬁ cult to ﬁ nd full matches 
for African, Asian, and Native Americans—mostly because of 
an insufﬁ cient number of UCB donors and the diversity of 
HLA types in different ethnic groups [16]. 
The real question is who should pay for UCB collection 
and storage—the individual donor, who currently has only 
a small prospect of using their cord blood, or society as a 
whole? We believe that it is the job of government to assure 
that people of all ethnic groups are informed and educated 
about donating UCB. Then, to facilitate UCB banking and 
the development of technological innovations for its storage 
and clinical utility, we recommend a national network that 
is a mixture of for proﬁ t, non-proﬁ t, and governmental 
organizations. 
Fisk and Roberts’s Response to Markwald and 
Mironov’s Viewpoint 
Markwald and Mironov argue that commercial 
UCB banking is ethically justiﬁ ed on the grounds that 
UCB transplantation is effective treatment for many 
haematological disorders, that autologous UCB is a useful 
future source of stem cells for the donor, and that there is no 
second chance to collect these cells. 
We did not dispute (indeed we acknowledged) the value 
of UCB HSCs for the treatment of many malignant and non-
malignant haematological disorders. However, evidence 
of their value derives from allogeneic HSCs from public 
UCB banks [27]. Like many in the routine UCB collection 
industry, Markwald and Mironov fail completely to distinguish 
between public and private banks in their discussion, and 
further neglect to mention that most transplants have been 
of allogeneic cells donated altruistically by non-related donor 
families. 
Markwald and Mironov state that the real question is who 
should pay for routine UCB collection and storage. However, 
they take no account of the considerable logistic burden 
this imposes, the extremely low chance that autologous cells 
will ever be used (less than one in 20,000), and the costs of 
routine UCB collection [9]. They also fail to mention that 
autologous UCB HSCs are frequently unsuitable for use for 
two reasons. First, they cannot cure inherited disorders (e.g., 
β-thalassaemia major or congenital bone marrow failure 
syndromes), and second, clinically hidden pre-leukaemic 
and/or leukaemic cells may be present in UCB at birth in 
children who years later develop full-blown leukaemia [28]. 
In addition, the authors introduce the irrelevant argument of 
the likely unsuitability of ESC transplants, with which, given 
the propensity of these transplants to cause teratomas, we 
agree [29].
Thus the real questions are, ﬁ rst, why should society in 
general, or the government as a representative of at least a 
substantial proportion of society, pay for a service not shown 
to be of any real use? (After all, as we pointed out, autologous 
HSCs are rarely required and there is no evidence that UCB 
can treat degenerative disease in elderly humans.) And 
second, why should commercial banks be allowed to continue 
to target vulnerable parents anxious to do the best for their 
children while making no mention of the low chance of use, 
of alternative sources of available stem cells (e.g., autologous 
marrow, a better source of non-haemopoietic stem cells), or 
of the risks of reducing stocks of allogeneic HSC in public 
UCB banks? 
Markwald and Mironov’s Response to Fisk and 
Roberts’s Viewpoint
We agree with Fisk and Roberts that exploiting 
the emotional vulnerabilities of expectant parents is 
unjustiﬁ able—thus we support regulation of UCB banking, 
monitoring, certiﬁ cation, and informed consent. But we 
disagree that there is a lack of solid scientiﬁ c evidence for 
UCB collection and that “future therapeutic possibilities 
are very hypothetical.” Research on stem cells is advancing 
rapidly, and stem cells derived from UCB are emerging as a 
reasonable ﬁ rst choice for the ﬁ eld of regenerative medicine.
Fisk and Roberts are inconsistent in their views. They 
claim that stem cells collected in UCB units often are 
not “in sufﬁ cient numbers for use against degenerative 
conditions” in adult life but then acknowledge that “the in 
vitro expandability of cord HSC numbers is sufﬁ cient for 
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transplantation into an adult.” They argue that private and 
public UCB collections create dramatically different “logistic 
burdens,” but in our experience, the syringes, paperwork, and 
level of personal distraction are generally the same for public 
or private banking.
We strongly disagree that private UCB banking has no 
future. While we anticipate a consolidation phase for this 
industry, surviving companies should be eager to acquire 
UCB units collected from competitors. If all stem cell 
sources were under a state monopoly—without private sector 
contribution—there would be less incentive or opportunity 
for fostering innovation in long-term storage, expansion, or 
phenotype characterization of UCB stem cells. The growth 
of new biotech companies focused on regenerative medicine 
would be discouraged, compromised, or undermined by the 
absence of competition, inadequate access to venture capital, 
and the typical resistance of state health-care systems and 
their afﬁ liated medical professionals to innovation. 
Fisk and Roberts are creating obfuscations by mixing 
“speculative cryobionic companies” that promise “immortality 
and eternity” with serious biotech companies and private 
UCB banks that focus on a realistic commercialisation of UCB 
stem cells as a platform for promoting new biotech initiatives.
The collection and storage of UCB stem cells is an 
opportunity for society to build a representative collection 
of UCB units that can improve the chances of identifying 
suitably matched donors for transplantation. Human 
ESCs are mired in ethical concerns and concerns about 
immunological intolerance. Autologous cells from the bone 
marrow or elsewhere lose their attractiveness if there is a 
genetic mutation or a progressive loss of “stemness” due to 
normal aging [30]. UCB cells offer the best short- and long-
term hope for treating sick children with cancers or adults 
with a variety of diseased organs and tissues. 
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